Despite active recruitment of CD45+ immune cells into the tumor microenvironment in response to LIVP-RFP therapy, only a few CD19+ cells were observed, with no more than two cells per field of view of NK1.1− and CD8+ cytotoxic lymphocyte-positive lymphocytes in the mouse (Figure 8 and Figure 9). The gene discussed is CD19; the disease is neoplasm.